Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$925.34
-1.8%
$918.98
$661.85
▼
$1,072.75
$58.19B0.48352,063 shs248,893 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$76.03
-2.8%
$70.22
$62.50
▼
$93.42
$14.81B0.972.89 million shs1.48 million shs
Biogen Inc. stock logo
BIIB
Biogen
$249.59
+1.0%
$236.18
$160.36
▼
$261.00
$36.89B0.11.21 million shs1.13 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$160.63
+0.8%
$190.87
$69.50
▼
$224.31
$34.74B1.442.82 million shs4.74 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.08%-4.00%+8.32%-9.40%+3.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.17%-0.04%+15.68%-4.12%+19.23%
Biogen Inc. stock logo
BIIB
Biogen
-1.70%-1.34%+1.66%+14.00%+47.16%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.24%-9.59%-18.89%-23.89%+126.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$925.34
-1.8%
$918.98
$661.85
▼
$1,072.75
$58.19B0.48352,063 shs248,893 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$76.03
-2.8%
$70.22
$62.50
▼
$93.42
$14.81B0.972.89 million shs1.48 million shs
Biogen Inc. stock logo
BIIB
Biogen
$249.59
+1.0%
$236.18
$160.36
▼
$261.00
$36.89B0.11.21 million shs1.13 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$160.63
+0.8%
$190.87
$69.50
▼
$224.31
$34.74B1.442.82 million shs4.74 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.08%-4.00%+8.32%-9.40%+3.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.17%-0.04%+15.68%-4.12%+19.23%
Biogen Inc. stock logo
BIIB
Biogen
-1.70%-1.34%+1.66%+14.00%+47.16%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.24%-9.59%-18.89%-23.89%+126.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.82
Moderate Buy$1,163.1825.70% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.82
Moderate Buy$104.4237.34% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$255.452.35% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.92
Moderate Buy$262.7563.57% Upside

Current Analyst Ratings Breakdown

Latest BBIO, ARGX, RVMD, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Biogen Inc. stock logo
BIIB
Biogen
Set Price Target$271.00
11/19/2026
Biogen Inc. stock logo
BIIB
Biogen
Set Price TargetBuy$270.00
11/18/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingBuy
11/17/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Reiterated RatingBuy$350.00
11/16/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetOverweight$1,215.00 ➝ $1,350.00
11/13/2026
argenex SE stock logo
ARGX
argenex
Lower Price TargetOverweight$1,190.00 ➝ $1,130.00
11/13/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOverweight$88.00 ➝ $91.00
11/13/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Lower Price TargetOverweight$272.00 ➝ $247.00
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/6/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$280.00 ➝ $350.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$250.00 ➝ $270.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$5.82B10.00$20.97 per share44.12$118.34 per share7.82
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M29.50N/AN/A($13.32) per share-5.71
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.73$22.47 per share11.11$128.01 per share1.95
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,000.27N/AN/A$11.10 per share14.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$28.6632.2926.330.8831.66%47.70%40.12%N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.04N/AN/AN/A-59.84%N/A-39.81%N/A
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34106.6615.662.853.37%9.38%5.69%2/5/2027 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$9.11N/AN/AN/AN/A-84.51%-51.97%N/A

Latest BBIO, ARGX, RVMD, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.35-$1.90+$0.45-$1.90$25.58 million$197.56 million
10/29/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5423-$0.42+$0.1223-$0.42$293.47 million$353.17 million
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
10/23/2026Q3 2026
argenex SE stock logo
ARGX
argenex
$7.44$7.80+$0.36$7.80N/A$1.75 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
2.09
2.03
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.44
8.36
8.34

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.89 million61.36 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839194.80 million167.08 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883216.29 million199.85 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Shares Up 5.3% - What's Next?
Revolution Medicines (NASDAQ:RVMD) Earns Buy Rating from HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenex stock logo

argenex NASDAQ:ARGX

$925.34 -16.70 (-1.77%)
Closing price 03:59 PM Eastern
Extended Trading
$901.68 -23.66 (-2.56%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$76.03 -2.15 (-2.75%)
Closing price 04:00 PM Eastern
Extended Trading
$76.56 +0.53 (+0.69%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$249.59 +2.46 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$248.14 -1.45 (-0.58%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$160.63 +1.20 (+0.75%)
Closing price 03:58 PM Eastern
Extended Trading
$161.99 +1.36 (+0.85%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.